China SXT Pharmaceuticals (SXTC) Total Current Liabilities (2018 - 2025)
Historic Total Current Liabilities for China SXT Pharmaceuticals (SXTC) over the last 8 years, with Q3 2025 value amounting to $6.0 million.
- China SXT Pharmaceuticals' Total Current Liabilities fell 6194.24% to $6.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $6.0 million, marking a year-over-year decrease of 6194.24%. This contributed to the annual value of $6.0 million for FY2025, which is 3246.35% down from last year.
- According to the latest figures from Q3 2025, China SXT Pharmaceuticals' Total Current Liabilities is $6.0 million, which was down 6194.24% from $6.0 million recorded in Q1 2025.
- In the past 5 years, China SXT Pharmaceuticals' Total Current Liabilities ranged from a high of $18.6 million in Q1 2021 and a low of $6.0 million during Q3 2025
- For the 5-year period, China SXT Pharmaceuticals' Total Current Liabilities averaged around $11.2 million, with its median value being $9.1 million (2023).
- In the last 5 years, China SXT Pharmaceuticals' Total Current Liabilities skyrocketed by 7026.26% in 2024 and then crashed by 6194.24% in 2025.
- Quarter analysis of 5 years shows China SXT Pharmaceuticals' Total Current Liabilities stood at $8.9 million in 2021, then dropped by 17.87% to $7.3 million in 2022, then grew by 26.17% to $9.2 million in 2023, then skyrocketed by 70.26% to $15.7 million in 2024, then tumbled by 61.94% to $6.0 million in 2025.
- Its Total Current Liabilities was $6.0 million in Q3 2025, compared to $6.0 million in Q1 2025 and $15.7 million in Q3 2024.